Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMB-001 in Glanzmann thrombasthenia
NL-OMON60350Phase 2Recruiting
- Sponsor
- Hemab Therapeutics
- Start
- May 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of sutacimig in Glanzmann thrombasthenia (GT) (3 arms), sponsored by Hemab Therapeutics. Started May 2024; status: recruiting.
02
Drugs
sutacimig
03
Conditions
Glanzmann thrombasthenia (GT)
Beyond the preview
Go deeper on NL-OMON60350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60350.